Extra Chromosome Sets Enhance Cell Mobility, New Study Finds

In a groundbreaking study published in the Journal of Cell Biology, scientists at Tulane University School of Medicine have uncovered a remarkable biological phenomenon that illuminates how polyploidy—a condition where cells acquire an extra set of chromosomes—fundamentally alters cell behavior to drive cancer progression. This investigation reveals that polyploid cells, which contain multiple chromosome sets beyond the usual diploid complement, trigger an intracellular stress signaling cascade that profoundly enhances their motility and capacity to engulf neighboring cells. These insights may herald novel therapeutic approaches aimed at mitigating the invasiveness of aggressive, therapy-resistant tumors.

Typically, animal cells maintain a diploid state with two sets of chromosomes, one inherited maternally and the other paternally. However, polyploidy emerges when cells either duplicate their genome in preparation for division but fail to undergo cytokinesis, or develop through alternative mechanisms. While polyploidy can serve essential physiological roles—such as enabling liver cells to enlarge and adapt to metabolic demands—it is increasingly recognized as a driver in malignancy, endowing cancer cells with heightened resistance to environmental stresses, therapeutic interventions, and enhanced proliferative capacity.

Led by Professor Wu-Min Deng, the Tulane research team employed Drosophila melanogaster larvae as an experimental model to elucidate the consequences of polyploidy on epithelial cell behavior. Through genetic manipulation, they induced polyploidy within these cells and observed a striking phenotypic transformation. Unlike their diploid counterparts, polyploid cells exhibited pronounced migratory aptitude, actively moving through tissues rather than remaining static. Intriguingly, these polyploid cells also engaged in phagocytosis, engulfing neighboring diploid cells, especially those undergoing apoptosis or otherwise compromised in health.

Mechanistically, the study identifies a critical link between increased chromosome content and augmented protein synthesis. The metabolic burden imposed by excess protein production leads to perturbations within the protein folding and synthesis machinery of the cell, resulting in elevated levels of reactive oxygen species (ROS). The accumulation of ROS activates the Jun N-terminal kinase (JNK) signaling pathway, a well-characterized stress response mechanism in cells. This pathway, once engaged, drives cytoskeletal reorganization and transcriptional changes that collectively potentiate cell motility and phagocytic activity.

Importantly, intervention experiments demonstrated that treating fruit flies with antioxidants effectively suppressed ROS accumulation, dampening JNK pathway activation and consequently reducing the migratory and engulfment capabilities of polyploid cells. Similarly, pharmacological inhibition of JNK signaling elicited comparable effects, underscoring the pivotal role of this pathway in reprogramming epithelial cell behavior in response to polyploidy-induced stress.

Expanding the relevance of these findings beyond model organisms, the researchers investigated human lung cancer cells engineered to undergo polyploidization. Consistent with their in vivo observations in Drosophila, polyploid human cancer cells displayed enhanced motility. When treated with antioxidants or JNK inhibitors, these human cells exhibited markedly reduced migration, confirming that the ROS-JNK axis activated by polyploidy is conserved across species and critical in modulating cancer cell dynamics.

This convergence of stress signaling and altered cell phenotype sheds light on why polyploid cancer cells accumulate in particularly aggressive, treatment-resistant tumors. By co-opting the stress response machinery, these cells gain units of advantage: they can invade adjacent tissues by migrating and simultaneously eliminate weaker competing cells through phagocytosis, effectively sculpting the tumor microenvironment to favor their survival and expansion.

The discovery that polyploidy-induced ROS production and JNK activation can be pharmacologically modulated suggests a promising therapeutic avenue. Drugs targeting elements of this stress-sensing axis could potentially inhibit the aggressive traits of polyploid cancer cells, limiting invasion and metastasis without affecting diploid cells that constitute normal tissue architecture. Such selectivity is crucial to minimizing side effects during cancer treatment.

Moreover, the study highlights the intricate interplay between genome duplication, metabolic stress, and cellular signaling pathways. It emphasizes the need for a deeper understanding of how subtle alterations in chromosome number can ripple through molecular networks to induce profound changes in cell behavior. This paradigm shift in cancer biology challenges the classical view of polyploidy solely as a consequence of genomic instability, positioning it instead as an active driver of tumor evolution and malignancy.

The research conducted by Deng et al. also opens new questions about the evolutionary advantages of polyploidy in normal physiology versus pathology. While polyploidy facilitates tissue growth and regeneration under controlled settings, its aberrant manifestation in cancer alters tissue homeostasis detrimentally. Deciphering the molecular switches that discriminate between beneficial and harmful polyploidy outcomes may aid in designing targeted interventions.

In conclusion, this landmark study elucidates how polyploid cells harness oxidative stress and the JNK signaling pathway to gain migratory and phagocytic capabilities, thereby contributing to the invasive potential of tumors. By bridging insights from fruit fly models to human cancer cells, the findings establish a conserved mechanistic framework with significant implications for cancer therapy. Targeting the stress-induced motility program of polyploid cells holds promise for developing strategies to combat aggressive cancers that currently elude effective treatment.

News Publication Date: 21-Apr-2026

Web References: http://dx.doi.org/10.1083/jcb.202507096

References: Zhou et al., 2026. Journal of Cell Biology